Last reviewed · How we verify
Alectinib - Usual
Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein.
Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein. Used for Metastatic non-small cell lung cancer with ALK rearrangement, Locally advanced or metastatic non-small cell lung cancer with ALK rearrangement.
At a glance
| Generic name | Alectinib - Usual |
|---|---|
| Also known as | Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily |
| Sponsor | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair |
| Drug class | ALK inhibitor |
| Target | ALK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ALK is a type of enzyme that can be mutated and become overactive in certain cancers. Alectinib works by blocking the activity of the ALK protein, which can help slow or stop the growth of cancer cells.
Approved indications
- Metastatic non-small cell lung cancer with ALK rearrangement
- Locally advanced or metastatic non-small cell lung cancer with ALK rearrangement
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Cough
Key clinical trials
- Pharmacogenomics ANDA 221517 SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alectinib - Usual CI brief — competitive landscape report
- Alectinib - Usual updates RSS · CI watch RSS
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair portfolio CI